Condition
Soft Tissue Bleeding
Total Trials
6
Recruiting
0
Active
0
Completed
6
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
4 trials in Phase 3/4
Results Transparency
50%
3 of 6 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (2)
P 3 (3)
P 4 (1)
Trial Status
Completed6
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05944419Not ApplicableCompleted
Influence of Neck Design on Peri-implant Hard and Soft Tissues
NCT02227992Phase 3Completed
The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study
NCT02227706Phase 3Completed
The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study
NCT03819244Not ApplicableCompleted
Comparison of Er,Cr:YSGG and Diode Lasers In Second Stage Implant Surgery
NCT01902459Phase 4Completed
EVARREST™ Fibrin Sealant Patch Post-Market Study
NCT00977925Phase 3CompletedPrimary
The Severe Soft Tissue Bleeding Study
Showing all 6 trials